Pfizer Vaccine Against Covid Is Over 90% Effective, Preliminary Analysis Of Phase 3 Studies Shows | Vaccine

Pharmaceuticals also said that so far they have found no serious safety concerns and hope to obtain an emergency use authorization in the US later this month.

The data still have not been peer reviewed, a step that is necessary for them to be published in a scientific journal. Pfizer said these steps will occur as soon as all study results are available. Pfizer said the interim analysis was done after 94 study participants developed Covid-19 and looked at how many of them received the vaccine compared to placebo.

Now, to confirm its effectiveness rate, the company said it will continue the study until it has 164 cases of Covid-19 among the participants.

Bill Gruber, one of Pfizer’s top vaccine scientists, said that number could be reached by early December, given the recent spike in infection rates in the US.

“I’m almost ecstatic,” Gruber said. “This is a great day for public health and the potential to lift us all out of the circumstances we find ourselves in now.”

“Today is a great day for science and humanity,” said Albert Bourla, Pfizer’s chief executive, in an official company statement.

“We are reaching this critical milestone in the development of our vaccine program at a time when the world needs it most, with infection rates reaching new records, hospitals nearly exceeding capacity and economies struggling to reopen,” Bourla said.

Learn more about the novel coronavirus in JN reports